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Abstract (250 words)  
 
Background: Global data on durability of first-line antiretroviral therapy (ART) in children with HIV is 
limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. 
Methods: Children <18-years initiating combination ART (≥2 nucleoside reverse transcriptase 
inhibitor (NRTI) plus non-NRTI (NNRTI) or boosted-protease inhibitor (PI)) were included. Switch to 
second-line was defined as:  (i) change across drug class (PI to NNRTI or vice versa) or within PI-class 
plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. 
Cumulative incidence of switch was calculated with death and loss-to-follow-up as competing risks.   
Results: Of 3,668 children included, median [IQR] age at ART initiation was 6.1 [1.7,10.5] years. 
Initial regimens were 32% PI, 34% nevirapine (NVP), 33% efavirenz-based. Median duration of 
follow-up from ART start was 5.4 [2.9,8.3] years.  Cumulative incidence of switch at 5 years was 21% 
(95% CI 20, 23), with lowest incidence in Russia/Ukraine and highest in UK/Ireland.  Median time to 
switch was 30 [15, 58] months, two-thirds of switches were related to treatment failure. In 
multivariable analysis, older age, severe immunosuppression and higher viral load at ART start, and 
NVP-based initial regimens were associated with increased risk of switch. Among those switched, 
65% had viral load <400c/mL at 12-months after start of second-line ART. 
Conclusions: One in five children switched to second-line by 5 years of ART, with two-thirds failure 
related.  Advanced HIV, older age and NVP-based regimens were associated with increased risk of 
switch. 
 
  
 3 
 
Introduction 
 
Worldwide, an estimated 2.1 million children aged<15 years were living with HIV in 2016, of 
whom 43% were accessing antiretroviral therapy (ART), with coverage expected to increase 
further[1].  Sustaining long-term viral suppression on ART throughout childhood and 
adolescence is a challenge[2].  Observational cohorts in middle and high-income countries 
with routine viral load monitoring have reported cumulative risk of virological failure in 
children ranging from 18% to 40% at 3 to 5 years after ART start[3-6]. As children currently 
require lifelong treatment, subsequent ART options will inevitably be required, and 
therefore programme planning and forecasting demand for paediatric formulations are 
needed.  
 
There remain limited and often conflicting estimates on the use of second-line ART in 
children, with wide variations in both clinical trials and observational cohorts, ranging from 
2% to 23% switching at 5 years after ART initiation[6-11].  This reflects variation in initial 
regimens, monitoring and switching strategies, availability of alternative regimens across 
studies and settings, and differences in the definitions of ‘switch’ used.  Some studies have 
restricted switch analyses to children with confirmed or unconfirmed virological 
failure[3,12], which may under-estimate the broader use of second-line treatment due to 
clinical and/or immunological failure, or major treatment limiting toxicities[6,13].   
 
In this study, we assessed time to switch to second-line ART for any cause and associated 
factors in the context of routine viral load monitoring, within the European Pregnancy and 
Paediatric HIV Cohort Collaboration (EPPICC), composed of cohorts across 16 European 
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countries and Thailand.  These cohorts offer long-term follow-up data to assess incidence of 
switch in routine-care settings across regions, which may inform other countries moving 
towards viral load monitoring[14]. 
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Methods 
Nineteen paediatric HIV observational cohorts across 17 countries contributed to an 
individual patient data meta-analysis carried out in December 2014.  Routine demographic, 
clinical, laboratory and treatment related data were pooled electronically using a modified 
HICDEP protocol (www.hicdep.org).  Children were included in this analysis if they were 
aged <18 years at start of a ‘standard’ combination ART regimen, defined as ≥2 nucleoside 
reverse-transcriptase inhibitors (NRTI) plus a non-NRTI (NNRTI) or boosted protease 
inhibitor (PI).  Children who participated in clinical trials of switching strategies or treatment 
interruption were excluded.  All cohorts received local ethics approval to transfer 
anonymised data for this study. 
  
Switch to second-line ART was defined as either (i) change across drug class (from NNRTI to 
PI or vice versa) or change within PI-class, plus change of ≥1 NRTI; (ii) change from single to 
dual PI; or (iii) an addition of a new drug class. Switches with documented reasons of 
simplification, tuberculosis prophylaxis or pregnancy were ignored.  This stringent definition 
of switch was used to reflect World Health Organization (WHO) and European guideline 
recommendations on the management of treatment failure in children[15-17].  In sensitivity 
analyses, we (i) ignored any switches during the first 6 months after ART initiation as these 
were unlikely to be related to treatment failure, (ii) relaxed our switch criteria by not 
requiring a change of ≥1 NRTI when switching across drug class or within PI-class, if the 
reason for switch was reported as failure, as some settings may need to preserve NRTIs.  
 
Among patients meeting our definition of switch we described the reasons reported for 
switching and explored evidence for clinical failure in those with missing reason (defined as 
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(i) viral load>1,000cps/mL; (ii) new CDC B/C event; or (iii) no CD4 gain from ART initiation, 
within the 6-months prior to switch).  We describe the characteristics at time of switch and 
virological response (<400 c/ml) at 12 and 24-months after switch.  
 
Time to switch was summarised using cumulative incidence, accounting for competing risks 
of death and loss to follow-up (LTFU). Children were at risk from ART start until the earliest 
of switch, death, last visit in paediatric care or 21st birthday.  Cohorts contributed follow-up 
data through to December 2013 except for Germany (until April 2012), Portugal (September 
2013) and Romania (October 2013).  LTFU was defined as children not known to have died 
or transferred to another clinic, whose last visit was more than two years before the cohort 
censoring date, or children reported as LTFU by their cohort.  
 
The associations between time to switch and characteristics at ART initiation were 
investigated using competing risks proportional hazards regression[18]. In univariable 
analysis, associations with the following factors at the start of ART were explored: age, sex, 
immunosuppression (WHO 2007 classification severe vs. non severe for age[19]), viral load 
(VL), CDC stage (C vs N/A/B), initial ART regimen, calendar year (1997-<2004, 2004-<2008, 
≥2008), region of cohort (UK & Ireland, Thailand, Russia & Ukraine (Eastern Europe) and 
remaining countries (Central & Western Europe)). The final multivariable model was 
selected using backwards elimination (exit probability p=0.05), with baseline hazard 
stratified by region.  Region was not included in the multivariable model as a covariate due 
to evidence of non-proportional hazards between regions. The functional form of 
continuous age was explored using regression splines. Differences in the effect of initial 
regimen on switch by age and year at ART start were explored. A sub-group analysis in 
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children aged <3 years in the UK/Ireland compared NVP+3NRTIs (rarely used in other 
regions) to other initial regimens. P-values are two-sided, and analyses were carried out 
using STATA v14.1 (Stata Corporation, College Station, Texas, USA). 
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Results 
Of 3,953 children who initiated ART, 3,668 (93%) met the study inclusion criteria (88 were 
excluded due to participation in clinical trials, 197 initiated on non-standard regimens). Half 
of the children were male; 90% were perinatally infected (Table 1).  
 
The three largest cohorts were from the UK/Ireland (29% of children), Thailand (19%), and 
Ukraine (13%).  Earliest year of ART initiation ranged from 1997 in UK/Ireland to 2002 in 
Thailand.  Approximately one-third of children started ART on efavirenz (EFV), nevirapine 
(NVP) or PI-based regimens (93% lopinavir/ritonavir). Median age at the start of ART was 6.1 
[IQR 1.7,10.5] years, and lower in children who initiated on PI- and NVP-based regimens 
than EFV-based regimens (Table 1).  A larger proportion of children initiating on PI-based 
regimens started treatment in later calendar years (≥2008) compared to other regimens.  
Children in the UK/Ireland and Thailand were more likely to initiate on NNRTI-based 
regimens compared to other regions where more children started on PI-based regimens. 
The median duration of follow-up after start of ART was 5.4 [2.9,8.3] years. The median gap 
between VL measurements after ART start varied across regions: 36, 26 and 13-14 weeks in 
Eastern Europe, Thailand and the rest of Europe, respectively.  
 
Switch to second-line 
Overall, 820 (22%) children met the definition of switch while 71 (2%) died and 374 (10%) 
were LTFU before switching.  There were significantly fewer patients LTFU in the UK/Ireland, 
more deaths in Thailand, and fewer patients switching in Eastern Europe (p<0.001) (Figure 
S1). Among those who switched, the median time from ART start to switch was 30 [16,58] 
months, the majority (72%) switching from an NNRTI- to a PI-based second-line regimen.   
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The overall cumulative incidence of switch was 14% (95% CI 13-15%) at 3 years, 21% (20-
23%) at 5 years and 27% (26-29%) at 7 years after ART start.   The cumulative incidence 
varied across regions, and these regional differences changed over time (Figure 1). At 1 year 
after ART start, Thailand and Eastern Europe had lowest cumulative incidence of switch at 
2% (1-3%), but it rapidly increased in Thailand to 16% (13-19%) by 3 years, a similar level to 
Western & Central Europe and UK/Ireland, and plateaued thereafter.  At 5 years after ART 
initiation, the cumulative incidence of switch was lowest in Eastern Europe at 12% (9-16%), 
and ranged from 20-25% in the other regions.   
 
Reasons for switch  
Among those switched to second-line ART, 652 (80%) had a documented reason for switch 
available, of which 63% were “treatment failure”, 11% “toxicity” and the remainder for 
“other reasons” including non-compliance.  Clinicians were more likely to report toxicity as 
the reason for switching from a PI-based regimen, whereas NVP-based regimens were more 
likely to be for failure (p<0.001) (Figure 2). Among the 168 (20%) children with missing 
reason for switch, 56% were likely to be due to treatment failure based on their clinical, 
immunological and virological data in the 6 months prior to switch. There was no significant 
difference in time to switch between those with and without a reason for switch reported 
(p=0.5).   
 
Factors at ART initiation associated with switch 
Children who initiated on NVP-based regimens had over two-fold increased risk of switch 
compared to children starting on PI-based regimens (adjusted sub-hazard ratio (sHR) 2.47, 
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95% CI 1.86-3.27, p=0.001), while those starting EFV-based regimens had a smaller 
increased risk (sHR 1.53 (1.16-2.02), p=0.002) (Table 2). In a sub-group analysis of 
UK/Ireland children aged <3 years, there was no difference in risk of switch between 
children taking NVP with a 3-NRTI (n=40) versus 2-NRTI (n=41) backbone (sHR 0.99 (0.51, 
1.91), p=0.97), with both groups at increased risk of switch compared to those starting a PI-
based regimen. The effect of age on hazard rate of switch was linear, with a 5% increase in 
risk of switch per year increase in age at start of ART (sHR 1.06, 95% CI 1.03-1.08, p<0.0001) 
(Figure 3).  Severe immunosuppression and higher VL at ART start were associated with 
increased risk of switch. After adjusting for these factors, sex, CDC stage and calendar year 
at ART initiation were not associated with risk of switch.  There was no evidence of an 
interaction between age at ART start and initial regimen (p=0.3).   
 
Sensitivity analyses 
When 63 switches in the first 6-months of ART were excluded, the cumulative proportion of 
switch was lower, at 19% (95% CI, 18-21%) at 5 years after ART start. Including switches 
across class or within PI class without a simultaneous change in ≥1NRTI, if the reported 
reason for switch was failure, increased the number of children switching to second-line by 
95 and the cumulative proportion of switch at 5 years to 24% (95% CI, 22-25%). Additional 
switches were predominately from Thailand (51%), and from an NNRTI to a PI-based 
regimen (82%). The median time to switch was comparable to that observed in the main 
analysis.  In multivariable analyses, the same factors remained associated with switch, with 
limited change to the point estimates, apart from the risk of switch for NVP-based regimens 
was reduced to 2.13 and 2.16 respectively. In addition, risk of switch was increased for 
children starting ART before 2004 when ignoring switches <6 months (data not shown).    
 11 
 
 
Characteristics at time of switch and response to second-line ART  
Among those switched to second-line, median age at switch was 11 [6,15] years, VL (n=671) 
was 4.1 [3.0,4.9] log10 copies/mL and CD4% (n=682) was 20 [11,29] %. The majority of 
children (72%) received a PI-based second-line regimen (lopinavir/ritonavir (57%), 
atazanavir (11%), darunavir (5%)), and <1% (n=7) received an integrase inhibitor (INSTI)-
based regimen.  The median duration of follow-up after start of the second-line regimen 
was 3.8 (1.8,6.5) years; among those with a VL measurement at 12 (n=561) and 24 (n=480) 
months after start of second-line, 65% and 69% were suppressed at <400 copies/mL, 
respectively.  
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Discussion 
This study of time to switch to second-line ART for any cause in children with routine viral 
load monitoring is the largest to date.  It includes many national cohorts across 
Europe[5,20], benefits from long duration of follow-up (over 5 years) and low levels of 
mortality and loss-to-follow-up.  There are four key findings from our study. First, 
approximately 80% of children remained on their first-line regimen at 5 years after ART 
initiation (allowing for minor drug modifications and treatment simplifications).  One-in-five 
children met our definition of switch at 5 years, although there were significant regional 
variations in the proportion switching, with lowest estimates of 12% in Eastern Europe and 
highest of 25% in the UK and Ireland.  
 
Second, older age at start of ART was associated with increased risk of switch, with no 
evidence that this effect varied by initial regimen.  Previous studies have reported increased 
risk of virological failure among children starting ART at older ages[21].  While our outcome 
was switch for all-causes, over two-thirds of the switches were failure-related.  The higher 
risk of switch in older children may reflect increased risk of failure as well as greater 
treatment options and/or willingness to switch adolescents experiencing failure compared 
to younger children. A recent global meta-analysis (including EPPICC), of approximately 
100,000 children on ART, the large majority from sub-Saharan Africa, also reported 
increased risk of switch to second-line with older age at ART start[22].   This highlights the 
need to consider novel adherence or support interventions for children initiating treatment 
at older ages, particularly adolescents[23].  This may include treatment simplification 
strategies such as the ‘weekends off’ short-cycle therapy.  The BREATHER trial randomised 
adolescents virologically suppressed on EFV-based regimens to continuous treatment versus 
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short treatment cycle of 5 days on and 2 days (weekends) off-ART.  The latter group 
reported high acceptability[24], maintained high levels of viral suppression, with low rates 
of switch at 48 and 144 weeks of follow-up and reported no difference in inflammation 
markers [25,26].  
 
Thirdly, children initiating a NVP-based regimen had increased risk of switch, as did those 
starting EFV (although to a lesser degree), compared to those starting PI-based regimens.  
This is consistent with findings from previous studies showing increased risk of switch to 
second-line in NVP- versus PI-based regimens[3,5,27].  This could partly reflect the 
reluctance of clinicians to switch children failing a PI-based regimen due to the difficulty in 
deciding what to switch to, and recommendations to first address adherence issues due to 
the high resistance barrier[17].  However, studies have also shown increased risk of 
virological failure for NVP- versus PI-based regimens[5,28], and a higher proportion of the 
switches from NVP-based regimens in our cohort were reported as failure-related.  These 
findings support PENTA and US guideline recommendations to consider PI-based first-line 
regimens in all children (aged>14 days) and adolescents[17,29]. Nonetheless NVP remains a 
widely used, low-cost, essential drug option for children in resource-limited settings with 
poor access to PIs[22,30].  It is important to note that the majority of children who initiated 
NVP in our cohort remained on it at 5 years (73%), suggesting those who tolerated and 
responded to NVP did achieve long durability on this first-line regimen.  
 
Outside of Eastern Europe, our estimates of switch at 5 years were remarkably similar 
across regions, despite wide variations in the initial regimens used, and age and immune 
status at start of ART.  Since, severe immunosuppression at ART initiation was confirmed as 
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a risk factor for switch in our study[11], one may have expected higher switch rates in 
Thailand which had both the highest proportion of children starting NNRTI-based regimens 
(93%) and who were severely immunocompromised.  The lower levels of switch observed in 
Thailand most likely reflect differences in frequency of viral load  testing, as well as 
availability/readiness to switch to second-line regimens.  
 
Comparison of unadjusted cumulative incidence estimates of switch across studies and 
contexts is challenging as the distributions of risk factors in heterogeneous populations is 
not taken into account. Notwithstanding this limitation, our overall estimate of switch to 
second-line of 21% at 5 years is comparable to recent findings from the Asia Pacific cohort, 
which reported 23% switch at 5 years among children with routine viral load monitoring[11].  
Importantly the authors report that children without viral load monitoring had a 53% lower 
incidence of switch compared to children with viral load monitoring. As more countries shift 
towards routine or targeted viral load monitoring[30], the use of second-line ART, which is 
currently very low (≤3%) in settings without viral load monitoring[22], is expected to 
increase following improved detection of treatment failure and efforts to improve 
availability of PI-based and INSTI-based regimens in paediatric formulations[31].  The global 
use of second-line ART may then reach similar levels to that observed in our cohort.    
 
The clinical implication of the shift to routine viral load testing remains unclear. The 
PENPACT-1 trial reported no difference in clinical outcomes when switching children early or 
late, at high (30,000 copies/ml) or low (1000 copies/ml) viral load levels, although the trial 
was conducted mainly in high-income countries. However, earlier switch did minimise the 
accumulation of drug resistance mutations in those initiating on NNRTI-based 
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regimens[7,32].  Similarly, recent studies of adult patients in sub-Saharan African (the large 
majority initiated on NNRTI-based regimens) have reported that delayed switch to second-
line after prolonged virological failure  was associated with accumulation of resistance 
mutations which limited the NRTI options for second-line ART[33], as well as increased risk 
of failure, morbidity and mortality on second-line[12,34,35].  These findings are likely to be 
generalisable to children in such settings. More information on accumulation of drug 
resistance mutations whilst on failing PI-based regimens is needed. 
 
Fourthly, over two-thirds of children in our cohort achieved viral suppression at 12 and 24 
months after switch to second-line.  This is broadly consistent with the prevalence of 
suppression at 1 year after switch reported in other paediatric cohorts [36-38].  However 
one-third of patients experienced viremia.  It is unclear if this is due to poor adherence or 
resistant virus. Further studies on the clinical outcomes on second and third-line ART in 
children and adolescents are warranted.   
 
There are some important limitations to this study. First, 20% of children switched to 
second-line had no reported reason for switch. Although for these children we used data on 
clinical status, CD4 and VL in the 6 months before switch to assess likelihood of the switch 
being failure-related; this may not reflect the true reason for switch. Second, there are 
unmeasured potential confounders including exposure to maternal/infant antiretroviral 
prophylaxis, adherence, resistance profile and availability of alternative regimens, all of 
which may influence the probability of switch.  
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In summary, in our cohort of children with routine viral load monitoring, a fifth had switched 
to second-line while the large majority remained on their first-line regimen at 5 years of 
ART.  These estimates provide an insight on the expected use of second-line regimen as the 
global paediatric HIV population matures and access to viral load monitoring expands. A 
commitment to the availability of affordable paediatric drugs with high resistance 
barriers[39, 40] and low pill burden will be essential to ensure these needs are met[31].  
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APPENDIX: COLLABORATING COHORTS 
Belgium: Hospital St Pierre Cohort, Brussels: Tessa Goetghebuer, MD, PhD; Marc Hainaut, 
MD PhD; Evelyne Van der Kelen, Research nurse; Marc Delforge, data manager. 
 
France: French Perinatal Cohort Study/Enquête Périnatale Française, ANRS EPF-CO10.  
Coordinating center, INSERM U1018, team 4 : Josiane Warszawski, Jerome Le Chenadec, 
Elisa Ramos, Olivia Dialla, Thierry Wack, Corine Laurent, Lamya Ait si Selmi, Isabelle 
Leymarie, Fazia Ait Benali, Maud Brossard, Leila Boufassa 
Participating sites (hospital name, city, main investigator): Hôpital Louis Mourier, Colombes, 
Dr Corinne Floch-Tudal; Groupe Hospitalier Cochin Tarnier Port-Royal, PARIS, Dr Ghislaine 
Firtion; Centre Hospitalier Intercommunal, Creteil, Dr Isabelle Hau; Centre Hospitalier 
Général, Villeneuve Saint Georges, Dr Anne Chace; Centre Hospitalier Général- Hôpital 
Delafontaine, Saint-Denis, Dr Pascal Bolot; Groupe Hospitalier Necker, Paris, Pr Stéphane 
Blanche; Centre hospitalier Francilien Sud, Corbeil Essonne, Dr Michèle Granier; Hôpital 
Antoine Béclère, Clamart, Pr Philippe Labrune 
Hôpital Jean Verdier, Bondy, Dr Eric Lachassine; Hôpital Trousseau, Paris, Dr Catherine 
Dollfus 
Hôpital Robert Debré, Paris, Dr Martine Levine; Hôpital Bicêtre, Le Kremlin Bicëtre, Dr 
Corinne Fourcade; Centre Hospitalier Intercommunal, Montreuil, Dr Brigitte Heller- Roussin; 
Centre Hospitalier Pellegrin, Bordeaux, Dr Camille Runel-Belliard; CHU Paule de Viguier, 
Toulouse, Dr Joëlle Tricoire; CHU Hôpital de l'Archet II, Nice, Dr Fabrice Monpoux; Groupe 
Hospitalier de la Timone, Marseille; CHU Hôpital Jean Minjoz, Besancon, Dr Catherine 
Chirouze; CHU Nantes Hotel Dieu, Nantes, Dr Véronique Reliquet; CHU Caen, Caen, Pr 
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Jacques Brouard; Institut d’Hématologie et Oncologie Pédiatrique, Lyon, Dr Kamila Kebaili; 
CHU Angers, Angers, Dr Pascale Fialaire; CHR Arnaud de Villeneuve, Montpellier, Dr Muriel 
Lalande; CHR Jeanne de Flandres, Lille, Dr Françoise Mazingue; Hôpital Civil, Strasbourg, Dr 
Maria Luisa Partisani 
 
Germany: German Paediatric & Adolescent HIV Cohort (GEPIC): Dr Christoph Königs, Dr 
Stephan Schultze-Strasser.  German clinical centers: Hannover Medical School, Dr. U. 
Baumann; Pediatric Hospital Krefeld, Dr. T. Niehues; University Hospital Düsseldorf, Dr. J. 
Neubert; University Hospital Hamburg, Dr. R. Kobbe; Charite Berlin, Dr. C. Feiterna-Sperling; 
University Hospital Frankfurt, Dr. C. Königs; University Hospital Mannheim, Dr. B. Buchholz; 
Munich University Hospital, Dr. G. Notheis 
 
Greece: Greek cohort. Vana Spoulou. 
 
Italy: for the Italian Register for HIV infection in Children: Pier Angelo Tovo (Turin), Luisa 
Galli, Elena Chiappini (Florence). Other participants: Osimani Patrizia (Ancona), Domenico 
Larovere (Bari), Maurizio Ruggeri (Bergamo), Giacomo Faldella, Francesco Baldi (Bologna) 
Raffaele Badolato (Brescia), Carlotta Montagnani, Elisabetta Venturini, Catiuscia Lisi 
(Florence), Antonio Di Biagio, Lucia Taramasso (Genua), Vania Giacomet, Paola Erba, 
Susanna Esposito, Rita Lipreri, Filippo Salvini, Claudia Tagliabue (Milan), Monica Cellini 
(Modena), Eugenia Bruzzese, Andrea Lo Vecchio (Naples), Osvalda Rampon, Daniele Donà 
(Padua), Amelia Romano (Palermo), Icilio Dodi (Parma), Anna Maccabruni (Pavia), Rita 
Consolini (Pisa), Stefania Bernardi, Hyppolite Tchidjou Kuekou, Orazio Genovese (Rome), 
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Paolina Olmeo (Sassari), Letizia Cristiano (Taranto), Antonio Mazza (Trento), Silvia Garazzino 
(Turin), Antonio Pellegatta (Varese).   
 
Netherlands: The ATHENA database is maintained by Stichting HIV Monitoring and 
supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the 
Centre for Infectious Disease Control of the National Institute for Public Health and the 
Environment.  
Clincal Centres (Paediatric care) 
Emma Kinderziekenhuis, Academic Medical Centre of the University of Amsterdam: HIV 
treating physicians: D. Pajkrt, H.J. Scherpbier. HIV nurse consultants: A.M. Weijsenfeld, A. 
van der Plas. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. 
Berkhout, M.T.E. Cornelissen, C.J. Schinkel, K.C.wolthers. Erasmus MC–Sophia, Rotterdam: 
HIV treating physicians: P.L.A. Fraaij, A.M.C. van Rossum. HIV nurse consultants: L.C. van der 
Knaap, E.G. Visser. HIV clinical virologists/chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A 
van Kampen, S.D. Pas. Radboudumc, Nijmegen: HIV treating physicians: S.S.V. Henriet, M. 
van de Flier, K. van Aerde. HIV nurse consultants: R. Strik-Albers. HIV clinical 
virologists/chemists: J. Rahamat-Langendoen, F.F. Stelma. Universitair Medisch Centrum 
Groningen, Groningen: HIV treating physicians: E. H. Schölvinck. HIV nurse consultants: H. de 
Groot-de Jonge. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van Leer-Buter, M. 
Knoester. Wilhelmina Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: L.J. Bont, 
S.P.M. Geelen, T.F.W. Wolfs. HIV nurse consultants: N. Nauta. HIV clinical 
virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
Grauls. 
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Coordinating Centre:  
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. 
Boender. Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data 
monitoring: D. Bergsma, S. Grivell, A. Jansen, M. Raethke, R. Meijering. Data collection: L. de 
Groot, M. van den Akker, Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Kruijne, C. 
Lodewijk, L. Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, M. Schoorl, A. 
Timmerman, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra. Patient 
registration: B. Tuk. 
 
Poland: Polish paediatric cohort: Magdalena Marczynska, Agnieszka Oldakowska, Jolanta 
Popielska, Urszula Coupland, Malgorzata Doroba. 
 
Portugal: Centro Hospitalar do Porto:Laura Marques, Carla Teixeira, Alexandre Fernandes. 
 
Portugal: Hospital de Santa Maria/CHLN: Filipa Prata.  
 
Romania: "Victor Babes" Hospital Cohort, Bucharest: Dr Luminita Ene, Cosmina Gingaras, 
Roxana Radoi. 
 
Russia: Federal State-owned Institution "Republican Clinical Infectious Diseases Hospital" of 
the Ministry of Health of the Russian Federation, St Petersburg: Liubov Okhonskaia, Evgeny 
Voronin, Milana Miloenko, Svetlana Labutina 
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Spain: CoRISPE-cat, Catalonia: financial support for CoRISPE-cat was provided by the 
Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida.  
Members: Hospital Universitari Vall d’Hebron, Barcelona (Pere Soler-Palacín, Maria 
Antoinette Frick and Santiago Pérez-Hoyos (statistician)), Hospital Universitari del Mar, 
Barcelona (Antonio Mur, Núria López), Hospital Universitari Germans Trias i Pujol, Badalona 
(María Méndez), Hospital Universitari JosepTrueta, Girona (Lluís Mayol), Hospital 
Universitari Arnau de Vilanova, Lleida (Teresa Vallmanya), Hospital Universitari Joan XXIII, 
Tarragona (Olga Calavia), Consorci Sanitari del Maresme, Mataró (Lourdes García), Hospital 
General de Granollers (Maite Coll), Corporació Sanitària Parc Taulí, Sabadell (Valentí 
Pineda), Hospital Universitari Sant Joan, Reus (Neus Rius), Fundació Althaia, Manresa (Núria 
Rovira), Hospital Son Espases, Mallorca (Joaquín Dueñas) and Hospital Sant Joan de Déu, 
Esplugues (Clàudia Fortuny, Antoni Noguera-Julian). 
Spain: CoRISPE-S and Madrid cohort: María José Mellado, Luis Escosa, Milagros García 
Hortelano, Talía Sainz (Hospital La Paz);María Isabel González- Tomé, Pablo Rojo, Daniel 
Blázquez (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San 
Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús 
Saavedra, Mar Santos, Mª Angeles Muñoz, Beatriz Ruiz, Carolina Fernandez  Mc Phee, 
Santiago Jimenez de Ory,Susana Alvarez (Hospital Gregorio Marañón); Miguel Ángel Roa 
(Hospital de Móstoles); José Beceiro (Hospital Príncipe de Asturias, Alcalá de Henares); Jorge 
Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren Apilanez 
(Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, Bilbao);  Elisa 
Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno Infantil, Las 
Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la Candelaria, Santa Cruz 
 24 
 
de Tenerife); Mónica Garzón, Vicente Román (Hospital de Lanzarote); Abián Montesdeoca, 
Mercedes Mateo (Complejo Universitario de Canarias, La Laguna-Tenerife),María José 
Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf Neth, Lola Falcón (Hospital 
Virgen del Rocio, Sevilla); Pedro Terol (Hospital Virgen de la Macarena, Sevilla); Juan Luis 
Santos (Hospital Virgen de las Nieves, Granada); David Moreno (Hospital Carlos Haya, 
Málaga); Francisco Lendínez (Hospital de Torrecárdenas, Almería); Ana Grande (Complejo 
Hospitalario Universitario Infanta Cristina, Badajoz); Francisco José Romero (Complejo 
Hospitalario de Cáceres); Carlos Pérez (Hospital de Cabueñes, Gijón); Miguel Lillo (Hospital 
de Albacete); Begoña Losada (Hospital Virgen de la Salud, Toledo); Mercedes Herranz 
(Hospital Virgen del Camino, Pamplona); Matilde Bustillo, Carmelo Guerrero (Hospital 
Miguel Servet, Zaragoza); Pilar Collado (Hospital Clínico Lozano Blesa, Zaragoza); José 
Antonio Couceiro (Complejo Hospitalario de Pontevedra); Amparo Pérez, Ana Isabel 
Piqueras, Rafael Bretón, Inmaculada Segarra (Hospital La Fe, Valencia); César Gavilán 
(Hospital San Juan de Alicante); Enrique Jareño (Hospital Clínico de Valencia); Elena 
Montesinos (Hospital General de Valencia); Marta Dapena (Hospital de Castellón); Cristina 
Álvarez (Hospital Marqués de Valdecilla, Santander); Ana Gloria Andrés (Hospital de León); 
Víctor Marugán, Carlos Ochoa (Hospital de Zamora); Santiago Alfayate, Ana Isabel 
Menasalvas (Hospital Virgen de la Arrixaca, Murcia); Elisa de Miguel (Complejo Hospitalario 
San Millán-San Pedro, Logroño) and Paediatric HIV-BioBank integrated in the Spanish AIDS 
Research Network and collaborating Centers. 
Funding: This work has been partially funded by the Fundación para la Investigación y 
Prevención de SIDA en España (FIPSE) (FIPSE 3608229/09 , FIPSE 240800/09, FIPSE 
361910/10),  Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de 
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Salud Carlos III (ISCIII) (RD12/0017/0035 and RD12/0017/0037), project as part of the Plan 
R+D+I and cofinanced by ISCIII- Subdirección General de Evaluación and Fondo Europeo de 
Desarrollo Regional (FEDER),Mutua Madrileña 2012/0077, Gilead Fellowship 2013/0071, FIS 
PI15/00694 ,CoRISpe (RED RIS RD06/0006/0035 y RD06/0006/0021).  
 
Sweden: Karolinska University Hospital, Stockholm (Lars Naver, Sandra Soeria-Atmadja, 
Vendela Hagås). 
 
Switzerland: Members of the Swiss HIV Cohort Study (SHCS) and the Swiss Mother and Child 
HIV Cohort Study: Aebi-Popp K, Asner S, Aubert V, Battegay M, Baumann M, Bernasconi E, 
Böni J, Brazzola P, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Duppenthaler A, Dollenmaier 
G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux CA, Grawe C, Günthard HF 
(President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, 
Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, Kouyos RD, 
Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner KJ, Müller, Nicca D, Paioni P, 
Pantaleo G, Polli Ch, Posfay-Barbe K, Rauch A, Rudin C (Chairman of the Mother & Child 
Substudy), Schmid P, Scherrer AU (Head of Data Centre), Speck R, Tarr P, Thanh Lecompte 
M, Trkola A, Vernazza P, Wagner N, Wandeler G, Weber R, Wyler CA, Yerly S.  Funding: the 
Swiss HIV Cohort Study is supported by the Swiss National Science Foundation (grant 
#148522), and by the SHCS research foundation. 
 
Thailand: Program for HIV Prevention & Treatment (PHPT). Participating hospitals: 
Lamphun: Pornpun Wannarit; Phayao Provincial Hospital: Pornchai Techakunakorn; 
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Chiangrai Prachanukroh: Rawiwan Hansudewechakul; Chiang Kham: Vanichaya 
Wanchaitanawong; Phan: Sookchai Theansavettrakul; Mae Sai: Sirisak Nanta; Prapokklao: 
Chaiwat Ngampiyaskul; Banglamung: Siriluk Phanomcheong; Chonburi: Suchat Hongsiriwon; 
Rayong: Warit Karnchanamayul; Bhuddasothorn Chacheongsao: Ratchanee 
Kwanchaipanich; Nakornping: Suparat Kanjanavanit; Somdej Prapinklao: Nareerat 
Kamonpakorn, Maneeratn Nantarukchaikul; Bhumibol Adulyadej: Prapaisri Layangool, 
Jutarat Mekmullica; Pranangklao: Paiboon Lucksanapisitkul, Sudarat Watanayothin; 
Buddhachinaraj: Narong Lertpienthum; Hat Yai: Boonyarat Warachit; Regional Health 
Promotion Center 6, Khon Kaen: Sansanee Hanpinitsak; Nong Khai: Sathit Potchalongsin; 
Samutsakhon: Pimpraphai Thanasiri, Sawitree Krikajornkitti; Phaholpolphayuhasena: 
Pornsawan Attavinijtrakarn; Kalasin: Sakulrat Srirojana; Nakhonpathom: Suthunya 
Bunjongpak; Samutprakarn: Achara Puangsombat; Mahasarakam: Sathaporn Na-Rajsima; 
Roi-et: Pornchai Ananpatharachai; Sanpatong: Noppadon Akarathum; Vachira Phuket: 
Weerasak Lawtongkum; Chiangdao: Prapawan Kheunjan, Thitiporn Suriyaboon, Airada 
Saipanya. 
Data management team: Kanchana Than-in-at, Nirattiya Jaisieng, Rapeepan Suaysod, 
Sanuphong Chailoet, Naritsara Naratee, and Suttipong Kawilapat. 
 
Ukraine: Paediatric HIV Cohort: Dr T. Kaleeva, Dr Y. Baryshnikova (Odessa Regional Centre 
for HIV/AIDS, Dr S. Soloha (Donetsk Regional Centre for HIV/AIDS), Dr N. Bashkatova 
(Mariupol AIDS Center), Dr I. Raus (Kiev City Centre for HIV/AIDS), Dr O. Glutshenko, Dr Z. 
Ruban (Mykolaiv Regional Centre for HIV/AIDS), Dr N. Prymak (Kryvyi Rih), Dr G. Kiseleva 
(Simferopol), Dr H. Bailey (UCL, London, UK).  Funding acknowledgement: PENTA 
Foundation. 
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UK & Ireland: Collaborative HIV Paediatric Study (CHIPS): CHIPS is funded by the NHS 
(London Specialised Commissioning Group) and has received additional support from 
Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Roche, Abbott, and Gilead 
Sciences.  The MRC Clinical Trials Unit at UCL is supported by the Medical Research Council 
(programme number MC_UU_12023/26). 
 
CHIPS Steering Committee: Hermione Lyall, Karina Butler, Katja Doerholt, Caroline Foster, 
Nigel Klein, Esse Menson, Andrew Riordan, Delane Shingadia, Gareth Tudor-Williams, Pat 
Tookey, Steve Welch. MRC Clinical Trials Unit: Intira Jeannie Collins, Claire Cook, Donna 
Dobson, Keith Fairbrother, Diana M. Gibb, Ali Judd, Lynda Harper, Francesca Parrott, Anna 
Tostevin, Nadine Van Looy. 
Participating hospitals: Republic of Ireland: Our Lady's Children’s Hospital Crumlin, Dublin: K 
Butler, A Walsh.  UK: Birmingham Heartlands Hospital, Birmingham: S Scott, Y Vaughan, S 
Welch; Blackpool Victoria Hospital, Blackpool: N Laycock; Bristol Royal Hospital for Children, 
Bristol: J Bernatoniene, A Finn, L Hutchison; Calderdale Royal Hospital, Halifax: G Sharpe; 
Central Middlesex Hospital, London: A Williams; Chelsea and Westminster Hospital, London: 
EGH Lyall, P Seery; Coventry & Warwickshire University Hospital, Coventry: P Lewis, K Miles; 
Derbyshire Children’s Hospital, Derby: B Subramaniam; Derriford Hospital, Plymouth: L 
Hutchinson, P Ward; Ealing Hospital, Middlesex: K Sloper; Eastbourne District General 
Hospital, Eastbourne: G Gopal; Glasgow Royal Hospital for Sick Children, Glasgow: C 
Doherty, R Hague, V Price; Great Ormond St Hospital for Children, London: A Bamford, H 
Bundy, M Clapson, J Flynn, DM Gibb, N Klein, V Novelli, D Shingadia; Halliwell Children’s 
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Centre, Bolton: P Ainsley-Walker; Harrogate District Hospital, Harrogate: P Tovey; Homerton 
University Hospital, London: D Gurtin; Huddersfield Royal Infirmary, Huddersfield: JP 
Garside; James Cook Hospital, Middlesbrough: A Fall; John Radcliffe Hospital, Oxford: D 
Porter, S Segal; King's College Hospital, London: C Ball, S Hawkins; Leeds General Infirmary, 
Leeds: P Chetcuti, M Dowie; Leicester Royal Infirmary, Leicester: S Bandi, A McCabe; Luton 
and Dunstable Hospital, Luton: M Eisenhut; Mayday University Hospital, Croydon: J 
Handforth; Milton Keynes General Hospital, Milton Keynes: PK Roy; Newcastle General 
Hospital, Newcastle: T Flood, A Pickering; Newham General Hospital, London: S 
Liebeschuetz; Norfolk & Norwich Hospital, Norwich: C Kavanagh; North Manchester General 
Hospital, Manchester: C Murphy, K Rowson, T Tan; North Middlesex Hospital, London: J 
Daniels, Y Lees; Northampton General Hospital, Northampton: E Kerr, F Thompson; 
Northwick Park Hospital Middlesex; M Le Provost, A Williams; Nottingham City Hospital, 
Nottingham: L Cliffe, A Smyth, S Stafford; Queen Alexandra Hospital, Portsmouth: A 
Freeman; Raigmore Hospital, Inverness: T Reddy; Royal Alexandra Hospital, Brighton: K 
Fidler; Royal Belfast Hospital for Sick Children, Belfast: S Christie; Royal Berkshire Hospital, 
Reading: A Gordon; Royal Children’s Hospital, Aberdeen: D Rogahn; Royal Cornwall Hospital, 
Truro: S Harris, L Hutchinson; Royal Devon and Exeter Hospital, Exeter: A Collinson, L 
Hutchinson; Royal Edinburgh Hospital for Sick Children, Edinburgh: L Jones, B Offerman; 
Royal Free Hospital, London: V Van Someren; Royal Liverpool Children’s Hospital, Liverpool: 
C Benson, A Riordan; Royal London Hospital, London: A Riddell; Royal Preston Hospital, 
Preston: R O’Connor; Salisbury District General Hospital, Salisbury: N Brown; Sheffield 
Children's Hospital, Sheffield: L Ibberson, F Shackley; Southampton General Hospital, 
Southampton: SN Faust, J Hancock; St George's Hospital, London: K Doerholt, S Donaghy, K 
Prime, M Sharland, S Storey; St Luke’s Hospital, Bradford: S Gorman; St Mary’s Hospital, 
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London: EGH Lyall, C Monrose, P Seery, G Tudor-Williams, S Walters; St Thomas’ Hospital 
(Evelina Children’s Hospital), London: R Cross, E Menson; Torbay Hospital, Torquay: J 
Broomhall, L Hutchinson; University Hospital Lewisham, London: D Scott, J Stroobant; 
University Hospital of North Staffordshire, Stoke On Trent: A Bridgwood, P McMaster; 
University Hospital of Wales, Cardiff: J Evans, T Gardiner; Wexham Park, Slough: R Jones; 
Whipps Cross Hospital, London: K Gardiner. 
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Table 1. Characteristics of children at ART initiation by initial ART regimen 
 
bPI 
(n=1191) 
EFV 
(n=1214) 
NVP 
(n=1263) 
Total 
(n=3668) 
 n % n % n % n % 
Male 559 47% 589 49% 599 47% 1747 48% 
Perinatal infection* 1110 93% 973 80% 1208 96% 3291 90% 
Age (years), median [IQR] 3.2 [0.7, 8.4] 9.5 [6.1, 12.6] 3.9 [0.9, 8.5] 6.1 [1.7, 10.5] 
 <1 357 30% 4 0% 340 27% 701 19% 
 1 - <3 224 19% 67 6% 226 18% 517 14% 
 3 - <6 182 15% 220 18% 202 16% 604 16% 
 6  -<11 233 20% 474 39% 347 27% 1054 29% 
 11+ 195 16% 449 37% 148 12% 792 22% 
CDC stage C 146 12% 155 13% 129 10% 430 12% 
CD4% in those <5yrs (n=1183/1614),  
median [IQR] 23 [16, 32] 16 [11, 22] 22 [14, 34] 21 [14, 32] 
CD4 count in those≥5yrs (n=1614/2054), 
median [IQR] 281 [134, 462] 202 [55, 360] 170 [43, 358] 220 [63, 388] 
WHO severely immunocompromised (n=2808) 436 48% 634 63% 508 57% 1578 56% 
HIV RNA (log10 copies/ml) (n=2518),  
median [IQR] 5.2 [4.5, 5.3] 5 [4.4, 5.4] 5.1 [4.4, 5.7] 5 [4.4, 5.6] 
Calendar year of ART initiation        
 1997 - <2004 127 11% 356 29% 516 41% 999 27% 
 2004 - <2008 357 30% 477 39% 498 39% 1332 36% 
 ≥2008 707 59% 381 31% 249 20% 1337 36% 
Region         
 UK/Ireland 201 17% 438 36% 436 35% 1075 29% 
 Eastern Europe 402 34% 122 10% 108 9% 632 17% 
 Central and Western  Europe 541 45% 407 34% 321 25% 1269 35% 
 Thailand 47 4% 247 20% 398 32% 692 19% 
bPI: boosted protease inhibitor; EFV: efavirenz; NVP: nevirapine; ART: antiretroviral therapy; IQR: interquartile range. *Non-perinatal route of 
infection reported as: parenteral (non-injected drug use) (5%), blood products/transfusion (2%), other (1%) or unknown (3%)
Table Click here to download Table EPPICC_Switch_Tables_and_Figure_Legends_FINAL.docx 
Table 2.  Cumulative incidence of switch at 5 years after ART initiation and factors associated with switch to second-line ART  
 
 
 
 
 
 
 
 
Proportional hazards regression model accounting for competing risks of death and LTFU.  
†Multivariable regression model stratified by region.  
SHR: Sub Hazard Ratio, aSHR: adjusted Sub Hazard Ratio, ART: Antiretroviral Therapy, PI: Protease Inhibitor, NRTI: Nucleoside Reverse 
Transcriptase Inhibitor, EFV: Efavirenz, NVP: Nevirapine
 Cumulative incidence (%)  
at 5 years (95% CI) 
Univariable model Multivariable model† 
 SHR (95% CI) P aSHR (95% CI) P 
First-line ART regimen      
  Boosted PI+NRTI 12 (10 - 15) 1 <0.0001 1 <.0001 
  EFV+2NRTI 23 (20 - 26) 1.94 (1.58 - 2.39)  1.53 (1.16 - 2.02)  
  NVP+2NRTI 27 (24 - 29) 2.23 (1.83 - 2.73)  2.47 (1.86 - 3.27)  
Age at ART initiation      
   Per 1 year increase  - 1.04 (1.03 - 1.06) <0.0001 1.06 (1.03 - 1.08) <0.001 
   <1 19 (16 - 22)) 0.85 (0.69 - 1.05) <0.0001 -  
   1 - <3 18 (16 - 22) 0.79 (0.62 - 0.99)    
   3 - <6 15 (12 - 19) 0.79 (0.64 - 0.99)    
   6 - <11 21 (18 - 24) 1    
   ≥ 11 32 (28 - 36) 1.45 (1.21 - 1.74)    
HIV RNA at ART initiation, c/mL       
  <100,000 17 (14 - 20) 0.83 (0.69 - 0.98) 0.03 0.74 (0.61 - 0.90) 0.003 
  ≥100,000 21, (19 - 24) 1  1  
WHO severely immunocompromised       
  No 16 (14 - 19) 1 0.01 1 0.04 
  Yes 23 (21 - 25) 1.26 (1.06 - 1.49)  1.23 (1.01 - 1.50)  
CDC stage C diagnosis      
  No 20 (19 - 22) 1 0.01 -  
  Yes 28 (24 - 33) 1.27 (1.05 - 1.54)    
Calendar year of ART initiation      
  1991 - <2004 27 (24 - 29) 1.53 (1.31 - 1.78) <0.0001 -  
  2004 - <2008 20 (18 - 22) 1    
  ≥2008 16 (13 - 20) 0.79 (0.64 - 0.98)    
Figure titles and legends 
 
Figure 1.  Cumulative incidence of switch to second-line ART by region 
 
Figure 2. Reasons reported for switch to second-line ART, by initial ART regimen  
 
Figure 3. Relative hazard of switch by age at ART initiation 
Footnote: Relative hazard for age predicted from a proportional hazard regression model 
including ART regimen, WHO immunosuppression status and viral load at ART initiation.  
Hazard rate is plotted relative to a child of age 6.7 years (the median age of the cohort), 
dashed lines represent the 95% CI. 
 
Figure S1. Type of censoring by region  
 
 
Figure 1 Click here to download Figure (.tif and .eps files only) Figure 1.TIF 
Figure 2 Click here to download Figure (.tif and .eps files only) Figure 2.TIF 
Figure 3 Click here to download Figure (.tif and .eps files only) Figure 3.TIF 
Figure S1 Click here to download Supplemental data/Appendix -published online only Figure
S1.TIF
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Abstract (250 words)  
 
Background: Global data on durability of first-line antiretroviral therapy (ART) in children with HIV is 
limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. 
Methods: Children <18-years initiating combination ART (≥2 nucleoside reverse transcriptase 
inhibitor (NRTI) plus non-NRTI (NNRTI) or boosted-protease inhibitor (PI)) were included. Switch to 
second-line was defined as:  (i) change across drug class (PI to NNRTI or vice versa) or within PI-class 
plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. 
Cumulative incidence of switch was calculated with death and loss-to-follow-up as competing risks.   
Results: Of 3,668 children included, median [IQR] age at ART initiation was 6.1 [1.7,10.5] years. 
Initial regimens were 32% PI, 34% nevirapine (NVP), 33% efavirenz-based. Median duration of 
follow-up from ART start was 5.4 [2.9,8.3] years.  Cumulative incidence of switch at 5 years was 21% 
(95% CI 20, 23), with lowest incidence in Russia/Ukraine and highest in UK/Ireland.  Median time to 
switch was 30 [15, 58] months, two-thirds of switches were related to treatment failure. In 
multivariable analysis, older age, severe immunosuppression and higher viral load at ART start, and 
NVP-based initial regimens were associated with increased risk of switch. Among those switched, 
65% had viral load <400c/mL at 12-months after start of second-line ART. 
Conclusions: One in five children switched to second-line by 5 years of ART, with two-thirds failure 
related.  Advanced HIV, older age and NVP-based regimens were associated with increased risk of 
switch. 
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Introduction 
 
Worldwide, an estimated 2.1 million children aged<15 years were living with HIV in 2016, of 
whom 43% were accessing antiretroviral therapy (ART), with coverage expected to increase 
further[1].  Sustaining long-term viral suppression on ART throughout childhood and 
adolescence is a challenge[2].  Observational cohorts in middle and high-income countries 
with routine viral load monitoring have reported cumulative risk of virological failure in 
children ranging from 18% to 40% at 3 to 5 years after ART start[3-6]. As children currently 
require lifelong treatment, subsequent ART options will inevitably be required, and 
therefore programme planning and forecasting demand for paediatric formulations are 
needed.  
 
There remain limited and often conflicting estimates on the use of second-line ART in 
children, with wide variations in both clinical trials and observational cohorts, ranging from 
2% to 23% switching at 5 years after ART initiation[6-11].  This reflects variation in initial 
regimens, monitoring and switching strategies, availability of alternative regimens across 
studies and settings, and differences in the definitions of ‘switch’ used.  Some studies have 
restricted switch analyses to children with confirmed or unconfirmed virological 
failure[3,12], which may under-estimate the broader use of second-line treatment due to 
clinical and/or immunological failure, or major treatment limiting toxicities[6,13].   
 
In this study, we assessed time to switch to second-line ART for any cause and associated 
factors in the context of routine viral load monitoring, within the European Pregnancy and 
Paediatric HIV Cohort Collaboration (EPPICC), composed of cohorts across 16 European 
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countries and Thailand.  These cohorts offer long-term follow-up data to assess incidence of 
switch in routine-care settings across regions, which may inform other countries moving 
towards viral load monitoring[14]. 
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Methods 
Nineteen paediatric HIV observational cohorts across 17 countries contributed to an 
individual patient data meta-analysis carried out in December 2014.  Routine demographic, 
clinical, laboratory and treatment related data were pooled electronically using a modified 
HICDEP protocol (www.hicdep.org).  Children were included in this analysis if they were 
aged <18 years at start of a ‘standard’ combination ART regimen, defined as ≥2 nucleoside 
reverse-transcriptase inhibitors (NRTI) plus a non-NRTI (NNRTI) or boosted protease 
inhibitor (PI).  Children who participated in clinical trials of switching strategies or treatment 
interruption were excluded.  All cohorts received local ethics approval to transfer 
anonymised data for this study. 
  
Switch to second-line ART was defined as either (i) change across drug class (from NNRTI to 
PI or vice versa) or change within PI-class, plus change of ≥1 NRTI; (ii) change from single to 
dual PI; or (iii) an addition of a new drug class. Switches with documented reasons of 
simplification, tuberculosis prophylaxis or pregnancy were ignored.  This stringent definition 
of switch was used to reflect World Health Organization (WHO) and European guideline 
recommendations on the management of treatment failure in children[15-17].  In sensitivity 
analyses, we (i) ignored any switches during the first 6 months after ART initiation as these 
were unlikely to be related to treatment failure, (ii) relaxed our switch criteria by not 
requiring a change of ≥1 NRTI when switching across drug class or within PI-class, if the 
reason for switch was reported as failure, as some settings may need to preserve NRTIs.  
 
Among patients meeting our definition of switch we described the reasons reported for 
switching and explored evidence for clinical failure in those with missing reason (defined as 
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(i) viral load>1,000cps/mL; (ii) new CDC B/C event; or (iii) no CD4 gain from ART initiation, 
within the 6-months prior to switch).  We describe the characteristics at time of switch and 
virological response (<400 c/ml) at 12 and 24-months after switch.  
 
Time to switch was summarised using cumulative incidence, accounting for competing risks 
of death and loss to follow-up (LTFU). Children were at risk from ART start until the earliest 
of switch, death, last visit in paediatric care or 21st birthday.  Cohorts contributed follow-up 
data through to December 2013 except for Germany (until April 2012), Portugal (September 
2013) and Romania (October 2013).  LTFU was defined as children not known to have died 
or transferred to another clinic, whose last visit was more than two years before the cohort 
censoring date, or children reported as LTFU by their cohort.  
 
The associations between time to switch and characteristics at ART initiation were 
investigated using competing risks proportional hazards regression[18]. In univariable 
analysis, associations with the following factors at the start of ART were explored: age, sex, 
immunosuppression (WHO 2007 classification severe vs. non severe for age[19]), viral load 
(VL), CDC stage (C vs N/A/B), initial ART regimen, calendar year (1997-<2004, 2004-<2008, 
≥2008), region of cohort (UK & Ireland, Thailand, Russia & Ukraine (Eastern Europe) and 
remaining countries (Central & Western Europe)). The final multivariable model was 
selected using backwards elimination (exit probability p=0.05), with baseline hazard 
stratified by region.  Region was not included in the multivariable model as a covariate due 
to evidence of non-proportional hazards between regions. The functional form of 
continuous age was explored using regression splines. Differences in the effect of initial 
regimen on switch by age and year at ART start were explored. A sub-group analysis in 
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children aged <3 years in the UK/Ireland compared NVP+3NRTIs (rarely used in other 
regions) to other initial regimens. P-values are two-sided, and analyses were carried out 
using STATA v14.1 (Stata Corporation, College Station, Texas, USA). 
 
  
 8 
 
Results 
Of 3,953 children who initiated ART, 3,668 (93%) met the study inclusion criteria (88 were 
excluded due to participation in clinical trials, 197 initiated on non-standard regimens). Half 
of the children were male; 90% were perinatally infected (Table 1).  
 
The three largest cohorts were from the UK/Ireland (29% of children), Thailand (19%), and 
Ukraine (13%).  Earliest year of ART initiation ranged from 1997 in UK/Ireland to 2002 in 
Thailand.  Approximately one-third of children started ART on efavirenz (EFV), nevirapine 
(NVP) or PI-based regimens (93% lopinavir/ritonavir). Median age at the start of ART was 6.1 
[IQR 1.7,10.5] years, and lower in children who initiated on PI- and NVP-based regimens 
than EFV-based regimens (Table 1).  A larger proportion of children initiating on PI-based 
regimens started treatment in later calendar years (≥2008) compared to other regimens.  
Children in the UK/Ireland and Thailand were more likely to initiate on NNRTI-based 
regimens compared to other regions where more children started on PI-based regimens. 
The median duration of follow-up after start of ART was 5.4 [2.9,8.3] years. The median gap 
between VL measurements after ART start varied across regions: 36, 26 and 13-14 weeks in 
Eastern Europe, Thailand and the rest of Europe, respectively.  
 
Switch to second-line 
Overall, 820 (22%) children met the definition of switch while 71 (2%) died and 374 (10%) 
were LTFU before switching.  There were significantly fewer patients LTFU in the UK/Ireland, 
more deaths in Thailand, and fewer patients switching in Eastern Europe (p<0.001) (Figure 
S1). Among those who switched, the median time from ART start to switch was 30 [16,58] 
months, the majority (72%) switching from an NNRTI- to a PI-based second-line regimen.   
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The overall cumulative incidence of switch was 14% (95% CI 13-15%) at 3 years, 21% (20-
23%) at 5 years and 27% (26-29%) at 7 years after ART start.   The cumulative incidence 
varied across regions, and these regional differences changed over time (Figure 1). At 1 year 
after ART start, Thailand and Eastern Europe had lowest cumulative incidence of switch at 
2% (1-3%), but it rapidly increased in Thailand to 16% (13-19%) by 3 years, a similar level to 
Western & Central Europe and UK/Ireland, and plateaued thereafter.  At 5 years after ART 
initiation, the cumulative incidence of switch was lowest in Eastern Europe at 12% (9-16%), 
and ranged from 20-25% in the other regions.   
 
Reasons for switch  
Among those switched to second-line ART, 652 (80%) had a documented reason for switch 
available, of which 63% were “treatment failure”, 11% “toxicity” and the remainder for 
“other reasons” including non-compliance.  Clinicians were more likely to report toxicity as 
the reason for switching from a PI-based regimen, whereas NVP-based regimens were more 
likely to be for failure (p<0.001) (Figure 2). Among the 168 (20%) children with missing 
reason for switch, 56% were likely to be due to treatment failure based on their clinical, 
immunological and virological data in the 6 months prior to switch. There was no significant 
difference in time to switch between those with and without a reason for switch reported 
(p=0.5).   
 
Factors at ART initiation associated with switch 
Children who initiated on NVP-based regimens had over two-fold increased risk of switch 
compared to children starting on PI-based regimens (adjusted sub-hazard ratio (sHR) 2.47, 
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95% CI 1.86-3.27, p=0.001), while those starting EFV-based regimens had a smaller 
increased risk (sHR 1.53 (1.16-2.02), p=0.002) (Table 2). In a sub-group analysis of 
UK/Ireland children aged <3 years, there was no difference in risk of switch between 
children taking NVP with a 3-NRTI (n=40) versus 2-NRTI (n=41) backbone (sHR 0.99 (0.51, 
1.91), p=0.97), with both groups at increased risk of switch compared to those starting a PI-
based regimen. The effect of age on hazard rate of switch was linear, with a 5% increase in 
risk of switch per year increase in age at start of ART (sHR 1.06, 95% CI 1.03-1.08, p<0.0001) 
(Figure 3).  Severe immunosuppression and higher VL at ART start were associated with 
increased risk of switch. After adjusting for these factors, sex, CDC stage and calendar year 
at ART initiation were not associated with risk of switch.  There was no evidence of an 
interaction between age at ART start and initial regimen (p=0.3).   
 
Sensitivity analyses 
When 63 switches in the first 6-months of ART were excluded, the cumulative proportion of 
switch was lower, at 19% (95% CI, 18-21%) at 5 years after ART start. Including switches 
across class or within PI class without a simultaneous change in ≥1NRTI, if the reported 
reason for switch was failure, increased the number of children switching to second-line by 
95 and the cumulative proportion of switch at 5 years to 24% (95% CI, 22-25%). Additional 
switches were predominately from Thailand (51%), and from an NNRTI to a PI-based 
regimen (82%). The median time to switch was comparable to that observed in the main 
analysis.  In multivariable analyses, the same factors remained associated with switch, with 
limited change to the point estimates, apart from the risk of switch for NVP-based regimens 
was reduced to 2.13 and 2.16 respectively. In addition, risk of switch was increased for 
children starting ART before 2004 when ignoring switches <6 months (data not shown).    
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Characteristics at time of switch and response to second-line ART  
Among those switched to second-line, median age at switch was 11 [6,15] years, VL (n=671) 
was 4.1 [3.0,4.9] log10 copies/mL and CD4% (n=682) was 20 [11,29] %. The majority of 
children (72%) received a PI-based second-line regimen (lopinavir/ritonavir (57%), 
atazanavir (11%), darunavir (5%)), and <1% (n=7) received an integrase inhibitor (INSTI)-
based regimen.  The median duration of follow-up after start of the second-line regimen 
was 3.8 (1.8,6.5) years; among those with a VL measurement at 12 (n=561) and 24 (n=480) 
months after start of second-line, 65% and 69% were suppressed at <400 copies/mL, 
respectively.  
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Discussion 
This study of time to switch to second-line ART for any cause in children with routine viral 
load monitoring is the largest to date.  It includes many national cohorts across 
Europe[5,20], benefits from long duration of follow-up (over 5 years) and low levels of 
mortality and loss-to-follow-up.  There are four key findings from our study. First, 
approximately 80% of children remained on their first-line regimen at 5 years after ART 
initiation (allowing for minor drug modifications and treatment simplifications).  One-in-five 
children met our definition of switch at 5 years, although there were significant regional 
variations in the proportion switching, with lowest estimates of 12% in Eastern Europe and 
highest of 25% in the UK and Ireland.  
 
Second, older age at start of ART was associated with increased risk of switch, with no 
evidence that this effect varied by initial regimen.  Previous studies have reported increased 
risk of virological failure among children starting ART at older ages[21].  While our outcome 
was switch for all-causes, over two-thirds of the switches were failure-related.  The higher 
risk of switch in older children may reflect increased risk of failure as well as greater 
treatment options and/or willingness to switch adolescents experiencing failure compared 
to younger children. A recent global meta-analysis (including EPPICC), of approximately 
100,000 children on ART, the large majority from sub-Saharan Africa, also reported 
increased risk of switch to second-line with older age at ART start[22].   This highlights the 
need to consider novel adherence or support interventions for children initiating treatment 
at older ages, particularly adolescents[23].  This may include treatment simplification 
strategies such as the ‘weekends off’ short-cycle therapy.  The BREATHER trial randomised 
adolescents virologically suppressed on EFV-based regimens to continuous treatment versus 
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short treatment cycle of 5 days on and 2 days (weekends) off-ART.  The latter group 
reported high acceptability[24], maintained high levels of viral suppression, with low rates 
of switch at 48 and 144 weeks of follow-up and reported no difference in inflammation 
markers [25,26].  
 
Thirdly, children initiating a NVP-based regimen had increased risk of switch, as did those 
starting EFV (although to a lesser degree), compared to those starting PI-based regimens.  
This is consistent with findings from previous studies showing increased risk of switch to 
second-line in NVP- versus PI-based regimens[3,5,27].  This could partly reflect the 
reluctance of clinicians to switch children failing a PI-based regimen due to the difficulty in 
deciding what to switch to, and recommendations to first address adherence issues due to 
the high resistance barrier[17].  However, studies have also shown increased risk of 
virological failure for NVP- versus PI-based regimens[5,28], and a higher proportion of the 
switches from NVP-based regimens in our cohort were reported as failure-related.  These 
findings support PENTA and US guideline recommendations to consider PI-based first-line 
regimens in all children (aged>14 days) and adolescents[17,29]. Nonetheless NVP remains a 
widely used, low-cost, essential drug option for children in resource-limited settings with 
poor access to PIs[22,30].  It is important to note that the majority of children who initiated 
NVP in our cohort remained on it at 5 years (73%), suggesting those who tolerated and 
responded to NVP did achieve long durability on this first-line regimen.  
 
Outside of Eastern Europe, our estimates of switch at 5 years were remarkably similar 
across regions, despite wide variations in the initial regimens used, and age and immune 
status at start of ART.  Since, severe immunosuppression at ART initiation was confirmed as 
 14 
 
a risk factor for switch in our study[11], one may have expected higher switch rates in 
Thailand which had both the highest proportion of children starting NNRTI-based regimens 
(93%) and who were severely immunocompromised.  The lower levels of switch observed in 
Thailand most likely reflect differences in frequency of viral load  testing, as well as 
availability/readiness to switch to second-line regimens.  
 
Comparison of unadjusted cumulative incidence estimates of switch across studies and 
contexts is challenging as the distributions of risk factors in heterogeneous populations is 
not taken into account. Notwithstanding this limitation, our overall estimate of switch to 
second-line of 21% at 5 years is comparable to recent findings from the Asia Pacific cohort, 
which reported 23% switch at 5 years among children with routine viral load monitoring[11].  
Importantly the authors report that children without viral load monitoring had a 53% lower 
incidence of switch compared to children with viral load monitoring. As more countries shift 
towards routine or targeted viral load monitoring[30], the use of second-line ART, which is 
currently very low (≤3%) in settings without viral load monitoring[22], is expected to 
increase following improved detection of treatment failure and efforts to improve 
availability of PI-based and INSTI-based regimens in paediatric formulations[31].  The global 
use of second-line ART may then reach similar levels to that observed in our cohort.    
 
The clinical implication of the shift to routine viral load testing remains unclear. The 
PENPACT-1 trial reported no difference in clinical outcomes when switching children early or 
late, at high (30,000 copies/ml) or low (1000 copies/ml) viral load levels, although the trial 
was conducted mainly in high-income countries. However, earlier switch did minimise the 
accumulation of drug resistance mutations in those initiating on NNRTI-based 
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regimens[7,32].  Similarly, recent studies of adult patients in sub-Saharan African (the large 
majority initiated on NNRTI-based regimens) have reported that delayed switch to second-
line after prolonged virological failure  was associated with accumulation of resistance 
mutations which limited the NRTI options for second-line ART[33], as well as increased risk 
of failure, morbidity and mortality on second-line[12,34,35].  These findings are likely to be 
generalisable to children in such settings. More information on accumulation of drug 
resistance mutations whilst on failing PI-based regimens is needed. 
 
Fourthly, over two-thirds of children in our cohort achieved viral suppression at 12 and 24 
months after switch to second-line.  This is broadly consistent with the prevalence of 
suppression at 1 year after switch reported in other paediatric cohorts [36-38].  However 
one-third of patients experienced viremia.  It is unclear if this is due to poor adherence or 
resistant virus. Further studies on the clinical outcomes on second and third-line ART in 
children and adolescents are warranted.   
 
There are some important limitations to this study. First, 20% of children switched to 
second-line had no reported reason for switch. Although for these children we used data on 
clinical status, CD4 and VL in the 6 months before switch to assess likelihood of the switch 
being failure-related; this may not reflect the true reason for switch. Second, there are 
unmeasured potential confounders including exposure to maternal/infant antiretroviral 
prophylaxis, adherence, resistance profile and availability of alternative regimens, all of 
which may influence the probability of switch.  
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In summary, in our cohort of children with routine viral load monitoring, a fifth had switched 
to second-line while the large majority remained on their first-line regimen at 5 years of 
ART.  These estimates provide an insight on the expected use of second-line regimen as the 
global paediatric HIV population matures and access to viral load monitoring expands. A 
commitment to the availability of affordable paediatric drugs with high resistance 
barriers[39, 40] and low pill burden will be essential to ensure these needs are met[31].  
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Delafontaine, Saint-Denis, Dr Pascal Bolot; Groupe Hospitalier Necker, Paris, Pr Stéphane 
Blanche; Centre hospitalier Francilien Sud, Corbeil Essonne, Dr Michèle Granier; Hôpital 
Antoine Béclère, Clamart, Pr Philippe Labrune 
Hôpital Jean Verdier, Bondy, Dr Eric Lachassine; Hôpital Trousseau, Paris, Dr Catherine 
Dollfus 
Hôpital Robert Debré, Paris, Dr Martine Levine; Hôpital Bicêtre, Le Kremlin Bicëtre, Dr 
Corinne Fourcade; Centre Hospitalier Intercommunal, Montreuil, Dr Brigitte Heller- Roussin; 
Centre Hospitalier Pellegrin, Bordeaux, Dr Camille Runel-Belliard; CHU Paule de Viguier, 
Toulouse, Dr Joëlle Tricoire; CHU Hôpital de l'Archet II, Nice, Dr Fabrice Monpoux; Groupe 
Hospitalier de la Timone, Marseille; CHU Hôpital Jean Minjoz, Besancon, Dr Catherine 
Chirouze; CHU Nantes Hotel Dieu, Nantes, Dr Véronique Reliquet; CHU Caen, Caen, Pr 
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Jacques Brouard; Institut d’Hématologie et Oncologie Pédiatrique, Lyon, Dr Kamila Kebaili; 
CHU Angers, Angers, Dr Pascale Fialaire; CHR Arnaud de Villeneuve, Montpellier, Dr Muriel 
Lalande; CHR Jeanne de Flandres, Lille, Dr Françoise Mazingue; Hôpital Civil, Strasbourg, Dr 
Maria Luisa Partisani 
 
Germany: German Paediatric & Adolescent HIV Cohort (GEPIC): Dr Christoph Königs, Dr 
Stephan Schultze-Strasser.  German clinical centers: Hannover Medical School, Dr. U. 
Baumann; Pediatric Hospital Krefeld, Dr. T. Niehues; University Hospital Düsseldorf, Dr. J. 
Neubert; University Hospital Hamburg, Dr. R. Kobbe; Charite Berlin, Dr. C. Feiterna-Sperling; 
University Hospital Frankfurt, Dr. C. Königs; University Hospital Mannheim, Dr. B. Buchholz; 
Munich University Hospital, Dr. G. Notheis 
 
Greece: Greek cohort. Vana Spoulou. 
 
Italy: for the Italian Register for HIV infection in Children: Pier Angelo Tovo (Turin), Luisa 
Galli, Elena Chiappini (Florence). Other participants: Osimani Patrizia (Ancona), Domenico 
Larovere (Bari), Maurizio Ruggeri (Bergamo), Giacomo Faldella, Francesco Baldi (Bologna) 
Raffaele Badolato (Brescia), Carlotta Montagnani, Elisabetta Venturini, Catiuscia Lisi 
(Florence), Antonio Di Biagio, Lucia Taramasso (Genua), Vania Giacomet, Paola Erba, 
Susanna Esposito, Rita Lipreri, Filippo Salvini, Claudia Tagliabue (Milan), Monica Cellini 
(Modena), Eugenia Bruzzese, Andrea Lo Vecchio (Naples), Osvalda Rampon, Daniele Donà 
(Padua), Amelia Romano (Palermo), Icilio Dodi (Parma), Anna Maccabruni (Pavia), Rita 
Consolini (Pisa), Stefania Bernardi, Hyppolite Tchidjou Kuekou, Orazio Genovese (Rome), 
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Paolina Olmeo (Sassari), Letizia Cristiano (Taranto), Antonio Mazza (Trento), Silvia Garazzino 
(Turin), Antonio Pellegatta (Varese).   
 
Netherlands: The ATHENA database is maintained by Stichting HIV Monitoring and 
supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the 
Centre for Infectious Disease Control of the National Institute for Public Health and the 
Environment.  
Clincal Centres (Paediatric care) 
Emma Kinderziekenhuis, Academic Medical Centre of the University of Amsterdam: HIV 
treating physicians: D. Pajkrt, H.J. Scherpbier. HIV nurse consultants: A.M. Weijsenfeld, A. 
van der Plas. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. 
Berkhout, M.T.E. Cornelissen, C.J. Schinkel, K.C.wolthers. Erasmus MC–Sophia, Rotterdam: 
HIV treating physicians: P.L.A. Fraaij, A.M.C. van Rossum. HIV nurse consultants: L.C. van der 
Knaap, E.G. Visser. HIV clinical virologists/chemists: C.A.B. Boucher, M.P.G Koopmans, J.J.A 
van Kampen, S.D. Pas. Radboudumc, Nijmegen: HIV treating physicians: S.S.V. Henriet, M. 
van de Flier, K. van Aerde. HIV nurse consultants: R. Strik-Albers. HIV clinical 
virologists/chemists: J. Rahamat-Langendoen, F.F. Stelma. Universitair Medisch Centrum 
Groningen, Groningen: HIV treating physicians: E. H. Schölvinck. HIV nurse consultants: H. de 
Groot-de Jonge. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van Leer-Buter, M. 
Knoester. Wilhelmina Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: L.J. Bont, 
S.P.M. Geelen, T.F.W. Wolfs. HIV nurse consultants: N. Nauta. HIV clinical 
virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
Grauls. 
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Coordinating Centre:  
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. 
Boender. Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data 
monitoring: D. Bergsma, S. Grivell, A. Jansen, M. Raethke, R. Meijering. Data collection: L. de 
Groot, M. van den Akker, Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Kruijne, C. 
Lodewijk, L. Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, M. Schoorl, A. 
Timmerman, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra. Patient 
registration: B. Tuk. 
 
Poland: Polish paediatric cohort: Magdalena Marczynska, Agnieszka Oldakowska, Jolanta 
Popielska, Urszula Coupland, Malgorzata Doroba. 
 
Portugal: Centro Hospitalar do Porto:Laura Marques, Carla Teixeira, Alexandre Fernandes. 
 
Portugal: Hospital de Santa Maria/CHLN: Filipa Prata.  
 
Romania: "Victor Babes" Hospital Cohort, Bucharest: Dr Luminita Ene, Cosmina Gingaras, 
Roxana Radoi. 
 
Russia: Federal State-owned Institution "Republican Clinical Infectious Diseases Hospital" of 
the Ministry of Health of the Russian Federation, St Petersburg: Liubov Okhonskaia, Evgeny 
Voronin, Milana Miloenko, Svetlana Labutina 
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Spain: CoRISPE-cat, Catalonia: financial support for CoRISPE-cat was provided by the 
Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida.  
Members: Hospital Universitari Vall d’Hebron, Barcelona (Pere Soler-Palacín, Maria 
Antoinette Frick and Santiago Pérez-Hoyos (statistician)), Hospital Universitari del Mar, 
Barcelona (Antonio Mur, Núria López), Hospital Universitari Germans Trias i Pujol, Badalona 
(María Méndez), Hospital Universitari JosepTrueta, Girona (Lluís Mayol), Hospital 
Universitari Arnau de Vilanova, Lleida (Teresa Vallmanya), Hospital Universitari Joan XXIII, 
Tarragona (Olga Calavia), Consorci Sanitari del Maresme, Mataró (Lourdes García), Hospital 
General de Granollers (Maite Coll), Corporació Sanitària Parc Taulí, Sabadell (Valentí 
Pineda), Hospital Universitari Sant Joan, Reus (Neus Rius), Fundació Althaia, Manresa (Núria 
Rovira), Hospital Son Espases, Mallorca (Joaquín Dueñas) and Hospital Sant Joan de Déu, 
Esplugues (Clàudia Fortuny, Antoni Noguera-Julian). 
Spain: CoRISPE-S and Madrid cohort: María José Mellado, Luis Escosa, Milagros García 
Hortelano, Talía Sainz (Hospital La Paz);María Isabel González- Tomé, Pablo Rojo, Daniel 
Blázquez (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San 
Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús 
Saavedra, Mar Santos, Mª Angeles Muñoz, Beatriz Ruiz, Carolina Fernandez  Mc Phee, 
Santiago Jimenez de Ory,Susana Alvarez (Hospital Gregorio Marañón); Miguel Ángel Roa 
(Hospital de Móstoles); José Beceiro (Hospital Príncipe de Asturias, Alcalá de Henares); Jorge 
Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren Apilanez 
(Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, Bilbao);  Elisa 
Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno Infantil, Las 
Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la Candelaria, Santa Cruz 
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de Tenerife); Mónica Garzón, Vicente Román (Hospital de Lanzarote); Abián Montesdeoca, 
Mercedes Mateo (Complejo Universitario de Canarias, La Laguna-Tenerife),María José 
Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf Neth, Lola Falcón (Hospital 
Virgen del Rocio, Sevilla); Pedro Terol (Hospital Virgen de la Macarena, Sevilla); Juan Luis 
Santos (Hospital Virgen de las Nieves, Granada); David Moreno (Hospital Carlos Haya, 
Málaga); Francisco Lendínez (Hospital de Torrecárdenas, Almería); Ana Grande (Complejo 
Hospitalario Universitario Infanta Cristina, Badajoz); Francisco José Romero (Complejo 
Hospitalario de Cáceres); Carlos Pérez (Hospital de Cabueñes, Gijón); Miguel Lillo (Hospital 
de Albacete); Begoña Losada (Hospital Virgen de la Salud, Toledo); Mercedes Herranz 
(Hospital Virgen del Camino, Pamplona); Matilde Bustillo, Carmelo Guerrero (Hospital 
Miguel Servet, Zaragoza); Pilar Collado (Hospital Clínico Lozano Blesa, Zaragoza); José 
Antonio Couceiro (Complejo Hospitalario de Pontevedra); Amparo Pérez, Ana Isabel 
Piqueras, Rafael Bretón, Inmaculada Segarra (Hospital La Fe, Valencia); César Gavilán 
(Hospital San Juan de Alicante); Enrique Jareño (Hospital Clínico de Valencia); Elena 
Montesinos (Hospital General de Valencia); Marta Dapena (Hospital de Castellón); Cristina 
Álvarez (Hospital Marqués de Valdecilla, Santander); Ana Gloria Andrés (Hospital de León); 
Víctor Marugán, Carlos Ochoa (Hospital de Zamora); Santiago Alfayate, Ana Isabel 
Menasalvas (Hospital Virgen de la Arrixaca, Murcia); Elisa de Miguel (Complejo Hospitalario 
San Millán-San Pedro, Logroño) and Paediatric HIV-BioBank integrated in the Spanish AIDS 
Research Network and collaborating Centers. 
Funding: This work has been partially funded by the Fundación para la Investigación y 
Prevención de SIDA en España (FIPSE) (FIPSE 3608229/09 , FIPSE 240800/09, FIPSE 
361910/10),  Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de 
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Salud Carlos III (ISCIII) (RD12/0017/0035 and RD12/0017/0037), project as part of the Plan 
R+D+I and cofinanced by ISCIII- Subdirección General de Evaluación and Fondo Europeo de 
Desarrollo Regional (FEDER),Mutua Madrileña 2012/0077, Gilead Fellowship 2013/0071, FIS 
PI15/00694 ,CoRISpe (RED RIS RD06/0006/0035 y RD06/0006/0021).  
 
Sweden: Karolinska University Hospital, Stockholm (Lars Naver, Sandra Soeria-Atmadja, 
Vendela Hagås). 
 
Switzerland: Members of the Swiss HIV Cohort Study (SHCS) and the Swiss Mother and Child 
HIV Cohort Study: Aebi-Popp K, Asner S, Aubert V, Battegay M, Baumann M, Bernasconi E, 
Böni J, Brazzola P, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Duppenthaler A, Dollenmaier 
G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux CA, Grawe C, Günthard HF 
(President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, 
Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, Kouyos RD, 
Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner KJ, Müller, Nicca D, Paioni P, 
Pantaleo G, Polli Ch, Posfay-Barbe K, Rauch A, Rudin C (Chairman of the Mother & Child 
Substudy), Schmid P, Scherrer AU (Head of Data Centre), Speck R, Tarr P, Thanh Lecompte 
M, Trkola A, Vernazza P, Wagner N, Wandeler G, Weber R, Wyler CA, Yerly S.  Funding: the 
Swiss HIV Cohort Study is supported by the Swiss National Science Foundation (grant 
#148522), and by the SHCS research foundation. 
 
Thailand: Program for HIV Prevention & Treatment (PHPT). Participating hospitals: 
Lamphun: Pornpun Wannarit; Phayao Provincial Hospital: Pornchai Techakunakorn; 
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Chiangrai Prachanukroh: Rawiwan Hansudewechakul; Chiang Kham: Vanichaya 
Wanchaitanawong; Phan: Sookchai Theansavettrakul; Mae Sai: Sirisak Nanta; Prapokklao: 
Chaiwat Ngampiyaskul; Banglamung: Siriluk Phanomcheong; Chonburi: Suchat Hongsiriwon; 
Rayong: Warit Karnchanamayul; Bhuddasothorn Chacheongsao: Ratchanee 
Kwanchaipanich; Nakornping: Suparat Kanjanavanit; Somdej Prapinklao: Nareerat 
Kamonpakorn, Maneeratn Nantarukchaikul; Bhumibol Adulyadej: Prapaisri Layangool, 
Jutarat Mekmullica; Pranangklao: Paiboon Lucksanapisitkul, Sudarat Watanayothin; 
Buddhachinaraj: Narong Lertpienthum; Hat Yai: Boonyarat Warachit; Regional Health 
Promotion Center 6, Khon Kaen: Sansanee Hanpinitsak; Nong Khai: Sathit Potchalongsin; 
Samutsakhon: Pimpraphai Thanasiri, Sawitree Krikajornkitti; Phaholpolphayuhasena: 
Pornsawan Attavinijtrakarn; Kalasin: Sakulrat Srirojana; Nakhonpathom: Suthunya 
Bunjongpak; Samutprakarn: Achara Puangsombat; Mahasarakam: Sathaporn Na-Rajsima; 
Roi-et: Pornchai Ananpatharachai; Sanpatong: Noppadon Akarathum; Vachira Phuket: 
Weerasak Lawtongkum; Chiangdao: Prapawan Kheunjan, Thitiporn Suriyaboon, Airada 
Saipanya. 
Data management team: Kanchana Than-in-at, Nirattiya Jaisieng, Rapeepan Suaysod, 
Sanuphong Chailoet, Naritsara Naratee, and Suttipong Kawilapat. 
 
Ukraine: Paediatric HIV Cohort: Dr T. Kaleeva, Dr Y. Baryshnikova (Odessa Regional Centre 
for HIV/AIDS, Dr S. Soloha (Donetsk Regional Centre for HIV/AIDS), Dr N. Bashkatova 
(Mariupol AIDS Center), Dr I. Raus (Kiev City Centre for HIV/AIDS), Dr O. Glutshenko, Dr Z. 
Ruban (Mykolaiv Regional Centre for HIV/AIDS), Dr N. Prymak (Kryvyi Rih), Dr G. Kiseleva 
(Simferopol), Dr H. Bailey (UCL, London, UK).  Funding acknowledgement: PENTA 
Foundation. 
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UK & Ireland: Collaborative HIV Paediatric Study (CHIPS): CHIPS is funded by the NHS 
(London Specialised Commissioning Group) and has received additional support from 
Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Roche, Abbott, and Gilead 
Sciences.  The MRC Clinical Trials Unit at UCL is supported by the Medical Research Council 
(programme number MC_UU_12023/26). 
 
CHIPS Steering Committee: Hermione Lyall, Karina Butler, Katja Doerholt, Caroline Foster, 
Nigel Klein, Esse Menson, Andrew Riordan, Delane Shingadia, Gareth Tudor-Williams, Pat 
Tookey, Steve Welch. MRC Clinical Trials Unit: Intira Jeannie Collins, Claire Cook, Donna 
Dobson, Keith Fairbrother, Diana M. Gibb, Ali Judd, Lynda Harper, Francesca Parrott, Anna 
Tostevin, Nadine Van Looy. 
Participating hospitals: Republic of Ireland: Our Lady's Children’s Hospital Crumlin, Dublin: K 
Butler, A Walsh.  UK: Birmingham Heartlands Hospital, Birmingham: S Scott, Y Vaughan, S 
Welch; Blackpool Victoria Hospital, Blackpool: N Laycock; Bristol Royal Hospital for Children, 
Bristol: J Bernatoniene, A Finn, L Hutchison; Calderdale Royal Hospital, Halifax: G Sharpe; 
Central Middlesex Hospital, London: A Williams; Chelsea and Westminster Hospital, London: 
EGH Lyall, P Seery; Coventry & Warwickshire University Hospital, Coventry: P Lewis, K Miles; 
Derbyshire Children’s Hospital, Derby: B Subramaniam; Derriford Hospital, Plymouth: L 
Hutchinson, P Ward; Ealing Hospital, Middlesex: K Sloper; Eastbourne District General 
Hospital, Eastbourne: G Gopal; Glasgow Royal Hospital for Sick Children, Glasgow: C 
Doherty, R Hague, V Price; Great Ormond St Hospital for Children, London: A Bamford, H 
Bundy, M Clapson, J Flynn, DM Gibb, N Klein, V Novelli, D Shingadia; Halliwell Children’s 
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Centre, Bolton: P Ainsley-Walker; Harrogate District Hospital, Harrogate: P Tovey; Homerton 
University Hospital, London: D Gurtin; Huddersfield Royal Infirmary, Huddersfield: JP 
Garside; James Cook Hospital, Middlesbrough: A Fall; John Radcliffe Hospital, Oxford: D 
Porter, S Segal; King's College Hospital, London: C Ball, S Hawkins; Leeds General Infirmary, 
Leeds: P Chetcuti, M Dowie; Leicester Royal Infirmary, Leicester: S Bandi, A McCabe; Luton 
and Dunstable Hospital, Luton: M Eisenhut; Mayday University Hospital, Croydon: J 
Handforth; Milton Keynes General Hospital, Milton Keynes: PK Roy; Newcastle General 
Hospital, Newcastle: T Flood, A Pickering; Newham General Hospital, London: S 
Liebeschuetz; Norfolk & Norwich Hospital, Norwich: C Kavanagh; North Manchester General 
Hospital, Manchester: C Murphy, K Rowson, T Tan; North Middlesex Hospital, London: J 
Daniels, Y Lees; Northampton General Hospital, Northampton: E Kerr, F Thompson; 
Northwick Park Hospital Middlesex; M Le Provost, A Williams; Nottingham City Hospital, 
Nottingham: L Cliffe, A Smyth, S Stafford; Queen Alexandra Hospital, Portsmouth: A 
Freeman; Raigmore Hospital, Inverness: T Reddy; Royal Alexandra Hospital, Brighton: K 
Fidler; Royal Belfast Hospital for Sick Children, Belfast: S Christie; Royal Berkshire Hospital, 
Reading: A Gordon; Royal Children’s Hospital, Aberdeen: D Rogahn; Royal Cornwall Hospital, 
Truro: S Harris, L Hutchinson; Royal Devon and Exeter Hospital, Exeter: A Collinson, L 
Hutchinson; Royal Edinburgh Hospital for Sick Children, Edinburgh: L Jones, B Offerman; 
Royal Free Hospital, London: V Van Someren; Royal Liverpool Children’s Hospital, Liverpool: 
C Benson, A Riordan; Royal London Hospital, London: A Riddell; Royal Preston Hospital, 
Preston: R O’Connor; Salisbury District General Hospital, Salisbury: N Brown; Sheffield 
Children's Hospital, Sheffield: L Ibberson, F Shackley; Southampton General Hospital, 
Southampton: SN Faust, J Hancock; St George's Hospital, London: K Doerholt, S Donaghy, K 
Prime, M Sharland, S Storey; St Luke’s Hospital, Bradford: S Gorman; St Mary’s Hospital, 
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London: EGH Lyall, C Monrose, P Seery, G Tudor-Williams, S Walters; St Thomas’ Hospital 
(Evelina Children’s Hospital), London: R Cross, E Menson; Torbay Hospital, Torquay: J 
Broomhall, L Hutchinson; University Hospital Lewisham, London: D Scott, J Stroobant; 
University Hospital of North Staffordshire, Stoke On Trent: A Bridgwood, P McMaster; 
University Hospital of Wales, Cardiff: J Evans, T Gardiner; Wexham Park, Slough: R Jones; 
Whipps Cross Hospital, London: K Gardiner. 
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